Friedman, Claire F. http://orcid.org/0000-0003-2621-8553
Manning-Geist, Beryl L.
Zhou, Qin
Soumerai, Tara
Holland, Aliya
Da Cruz Paula, Arnaud http://orcid.org/0000-0001-7694-8760
Green, Hunter http://orcid.org/0009-0002-3944-6803
Ozsoy, Melih Arda
Iasonos, Alexia
Hollmann, Travis
Leitao, Mario M. Jr.
Mueller, Jennifer J.
Makker, Vicky
Tew, William P.
O’Cearbhaill, Roisin E. http://orcid.org/0000-0001-8217-4554
Liu, Ying L.
Rubinstein, Maria M.
Troso-Sandoval, Tiffany
Lichtman, Stuart M.
Schram, Alison http://orcid.org/0000-0002-6070-2413
Kyi, Chrisann
Grisham, Rachel N.
Causa Andrieu, Pamela
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Aghajanian, Carol
Weigelt, Britta http://orcid.org/0000-0001-9927-1270
Hensley, Martee L.
Zamarin, Dmitriy http://orcid.org/0000-0002-0094-0161
Funding for this research was provided by:
EIF | Stand Up To Cancer
U.S. Department of Health & Human Services | National Institutes of Health (P30 CA008748)
Bristol-Myers Squibb
Breast Cancer Research Foundation
Cycle for Survival
GOG Foundation
Article History
Received: 12 July 2023
Accepted: 25 March 2024
First Online: 23 April 2024
Competing interests
: C.F.F. reports ongoing institutional research support from Merck, Bristol Myers Squibb, AstraZeneca, Mersana, Hotspot Therapeutics, Immunocore, Marengo and Volastra; consulting fees from Bristol Myers Squibb, Seagen, Aadi Biosciences and Eli Lily; honoraria for lectures from OncLive; meeting/travel support by Puma Biotechnology; and participation on data safety monitoring board or advisory board of Merck, Genentech and Marengo (all uncompensated). A.I. reports consulting fees from Mylan. T.H. is currently employed by Bristol Myers Squibb and has received research funding from Calico Labs, Bristol Myers Squibb and PICI. M.M.L. reports research funding paid to the institution from KCI/Acelity; ad hoc speaker for Intuitive Surgical; and advisory board participation for Johnson & Johnson/Ethicon and Takeda. V.M. reports meeting/travel support from Eisai and Merck; participation on data safety monitoring or advisory boards of Duality, Merck, Karyopharm, Exelexis, Eisai, Karyopharm, Bristol Myers Squibb, Clovis, Faeth Immunocore, Morphosys, AstraZeneca, Novartis, GlaxoSmithKline and Bayer (all uncompensated); and study support to the institution from Merck, Eisai, AztraZeneca, Faeth Immunocore, Karyopharm, Zymeworks, Duality, Clovis, Bayer and Takeda. R.E.O. reports personal fees from Tesaro/GlaxoSmithKline, Regeneron, R-PHARM, Seattle Genetics, Fresenius Kabi, the Gynecologic Oncology Foundation, Bayer, Curio, Miltenyi, 2seventybio and Immunogen and Other from Hitech Health, all outside the submitted work. She is an uncompensated steering committee member for the PRIMA, Moonstone (Tesaro/GlaxoSmithKline) and DUO-O (AstraZeneca) studies and an uncompensated advisor for Carina Biotech. Her institute receives funding for clinical research from Bayer/Celgene/Juno, Tesaro/GlaxoSmithKline, Merck, the Ludwig Cancer Institute, AbbVie/StemCentrx, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, MarkerTherapeutics, Syndax Pharmaceuticals, Genmab/Seagen Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, Acrivon, Lyell Immunopharma and the Gynecologic Oncology Foundation. Y.L.L. reports institutional research funding from Repare Therapeutics, AstraZeneca and GlaxoSmithKline; honoraria from Total Health and Sarah Lawrence College; and travel/meeting support by AstraZeneca, all outside the submitted work. M.M.R. reports research funding from Merk, Zentalis and AstraZeneca. A.S. reports advisory board participation with Relay Therapeutics, Mersana and Merus; consulting with Blueprint Bio and Flagship Pioneering; steering committee participation with Merus and Pfizer; research funding paid to the institution from AstraZeneca, ArQule, BeiGene/Springworks, Black Diamond Therapeutics, Elevation Oncology, Kura, Eli Lilly, Merus, Northern Biologics, Pfizer, PMV Pharma, Relay, Repare Therapeutics, Revolution Medicine and Surface Oncology; and food and beverage from PUMA and Repare Therapeutics. C.K. reports grant funding from the Conquer Cancer Foundation; grant funding paid to the institution from Merus, Gritstone and Bristol Myers Squibb; and consulting fees from Scenic Immunology B.V. and OncLive. R.N.G. reports honoraria from GlaxoSmithKline, AstraZeneca, Natera, Springworks, Corcept, MJH and PER. C.A. reports clinical trial funding paid to the institution from AstraZeneca; consulting fees (advisory board) from Eisai/Merck, Roche/Genentech, AbbVie, AstraZeneca/Merck and Repare Therapeutics; advisory board participation (uncompensated) for Blueprint Medicine; and leadership/fiduciary roles for the GOG Foundation Board of Directors (travel cost reimbursement) and the NRG Oncology Board of Directors (uncompensated). B.W. reports a research grant from REPARE Therapeutics paid to the institution, outside the submitted work. M.L.H. reports advisory board participation at Aadi Bioscience, GlaxoSmithKline, Thrive Bioscience and Eli Lilly; an immediate family member who is employed by Sanofi; and service as a CME faculty speaker for Research to Practice. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy, which supports research in the Wherry laboratory; an advisor for Danger Bio, Marengo, Janssen, NewLimit, Pluto Immunotherapeutics, Related Sciences, Santa Ana Bio, Synthekine and Surface Oncology; and is a founder of and holds stock in Surface Oncology, Danger Bio and Arsenal Biosciences. D.Z. reports institutional research support from AstraZeneca, Merck, Plexxikon, Synthekine and Genentech; consulting fees from AstraZeneca, Synthekine, Astellas, Tessa Therapeutics, Memgen, Celldex, Crown Biosciences, Hookipa Biotech, Kalivir, Xencor and GlaxoSmithKline; royalties from Merck; and stock options from Accurius Therapeutics, ImmunOS Therapeutics and Calidi Biotherapeutics, all outside the submitted work. The other authors do not have potential conflicts of interest to declare.